Trisenox® (arsenic trioxide) in patients with myelodysplastic syndromes (MDS):: Preliminary results of a phase I/II study.

被引：0

作者：

Vey, N

Dreyfus, F

Guerci, A

Fenaux, P

Dombret, H

Burnett, AK

Bosly, A

Feremans, W

Bowen, DT

Heiskala, M

机构：

[1] Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales

[2] Clin Univ Mt Godinne, Yvoir, Belgium

[3] Erasme Univ Hosp, Brussels, Belgium

[4] Ninewells Hosp, Dundee DD1 9SY, Scotland

[5] Celll Therapeut Inc, Clin, Seattle, WA USA

来源：

BLOOD | 2004年 / 104卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1433

引用

页码：401A / 402A

页数：2

共 50 条

[41] Risk factors of myelodysplastic syndromes (MDS): A case-control study.
Strom, SS
Gu, Y
Gruschkus, SK
Estey, EH
BLOOD, 2004, 104 (11) : 24A - 24A
[42] A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes
Wei, Wei
Zhou, Fan
Zhang, Yizi
Guo, Lieping
Shi, Haotian
Hou, Jian
LEUKEMIA RESEARCH, 2012, 36 (06) : 715 - 719
[43] Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
Richard-Carpentier, Guillaume
DeZern, Amy E.
Takahashi, Koichi
Konopleva, Marina Y.
Loghavi, Sanam
Masarova, Lucia
Alvarado, Yesid
Ravandi, Farhad
Bravo, Guillermo Montalban
Naqvi, Kiran
Sasaki, Koji
Delumpa, Ricardo
Kwari, Monica
Sekeres, Mikkael A.
Nazha, Aziz
Roboz, Gail J.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
DiNardo, Courtney D.
BLOOD, 2019, 134
[44] A Phase 2 Study of Combination Therapy With Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
Sekeres, Mikkael A.
Maciejewski, Jaroslaw P.
Erba, Harry P.
Afable, Manuel
Englehaupt, Ricki
Sobecks, Ronald
Advani, Anjali
Seel, Sherry
Chan, Josephine
Kalaycio, Matt E.
CANCER, 2011, 117 (06) : 1253 - 1261
[45] Phase I/II study of arsenic trioxide (Trisenox) in combination with imatinib mesylate (Gleevec, STI571) in patients with Gleevec-resistant chronic myelogenous leukemia in chronic phase.
Mauro, MJ
Deininger, MW
O'Dwyer, ME
Maziarz, RT
Walker, T
Kurilik, G
Druker, BJ
BLOOD, 2002, 100 (11) : 781A - 781A
[46] Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study
Modak, Shakeel
Zanzonico, Pat
Carrasquillo, Jorge A.
Kushner, Brian H.
Kramer, Kim
Cheung, Nai-Kong V.
Larson, Steven M.
Pandit-Taskar, Neeta
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (02) : 231 - 237
[47] ARSENIC TRIOXIDE AS RADIOSENSITIZER FOR 131I-MIBG THERAPY: RESULTS OF A PILOT PHASE II STUDY
Modak, Shakeel
Pandit-Taskar, Neeta
Carrasquillo, Jorge
Kramer, Kim
Kushner, Brian H.
Zanzonico, Pat
Smith-Jones, Peter
Larson, Steven
Cheung, Nai-Kong V.
PEDIATRIC BLOOD & CANCER, 2010, 55 (05) : 888 - 888
[48] TREATMENT WITH VNP40101M (CLORETAZINE?) IN PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES (MDS): RESULTS OF A SUBSET POPULATION IN A PHASE II STUDY
Mufti, G.
Rizzieri, D.
Vey, N.
Hudak, D.
Karp, J.
Giles, E.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 94 - 95
[49] RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)
Schuler, E.
Schemenau, J.
Giagounidis, A.
Haase, D.
Bueshce, G.
Platzbecker, U.
Nolte, F.
Goetze, K.
Schlenk, R. F.
Ganser, A.
Letsch, A.
Luebbert, M.
Schafhausen, P.
Bug, G.
Germing, U.
LEUKEMIA RESEARCH, 2015, 39 : S62 - S62
[50] Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS).
Garcia-Manero, G.
Minden, M.
Estrov, Z.
Verstovsek, S.
Newsome, W. M.
Reid, G.
Besterman, J.
Li, Z.
Pearce, L.
Martell, R.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 337S - 337S

← 1 2 3 4 5 →